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How small can things get? Pushing the boundaries in miniaturization means
going frommilli to micro and frommicro to nano. In designing microfluidic plat-
forms for use in biological research, Clausell-Tormos et al. now develop a sys-
tem with microcompartments with volume over 1,000-fold smaller than the
smallest volumes used in microtiter-plate based assays. They also show that
single or multiple human cells, as well as multicellular organisms such as C. el-
egans, can be compartmentalized and replicate in these systems and remain
fully viable for several days. The decrease in size and amount of reagents re-
quired, accompanied by the increase in rate of readout available, makes this
a very attractive set up for development of high-throughput, cell-based assays.
(Figure credits Clausell-Tormos et al.)
Plants Beware of Bugs with Peptidoglycans
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In this issue, Erbs et al. show that peptidoglycan (PGN) from two Gram-negative plant pathogenic bacteria, Xanthomonas
campestris pv. campestris and Agrobacterium tumefaciens, elicit the innate immune response in Arabidopsis thaliana, in par-
ticular transcription of the defence gene PR1, oxidative burst, medium alkalinization, and formation of callose. Highly purified
muropeptides from PGNs are more effective elicitors of early defense responses than native PGN. Therefore, PGN and its
constituents represent a new microbe-associated molecular pattern (MAMP) in plant-bacterial interactions. Based on the
structure of muropeptide components described, differing defense-eliciting abilities appear to depend on subtle structural
differences in either carbohydrate or peptide groups.
When an Enzyme Just Won’t Let Go
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Polyether ionophore antibiotics such as nanchangmycin are widely used in veterinary medicine and in animal husbandry
for the treatment of diseases such as coccidiosis in poultry and as growth promotants. Although the basic outlines of poly-
ether biosynthesis have been known for about 25 years, only recently has it become possible to investigate the biological for-
mation of these complex polyketides at the enzymatic and molecular genetic level. Although nanchangmycin is apparently
generated by a polyfunctional, modular polyketide synthase, Liu et al. have now established that all the intermediates of
the pathway remain enzyme-bound until they are finally hydrolytically released by the dedicated thioesterase encoded by
the nanE gene.
Watch Out Polo-Box Domain, Here Comes Poloxin
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Polo-like kinase 1 (Plk1) is a key player for multiple stages of mitosis and has been
established as a target for anticancer therapy. Usually, inhibitors of Plk1 target the
conserved ATP-binding site. Reindl et al. now provide proof-of-principle that Plk1
can alternatively be targeted by small-molecules that inhibit the protein-protein in-
teractions required for correct intracellular localization of Plk1. Authors identified
the natural product Thymoquinone and a synthetic derivative, dubbed ‘‘Poloxin,’’
as the first known inhibitors of the polo-box domain (PBD), a recently discovered
protein domain which mediates intracellular localization of Plk1. (Figure credits Re-
indl et al.)
Down Which Metabolic Pathway Intermediate
Went
PAGE 467
One plausible mechanism of enzyme evolution is optimization of a single activity
from a catalytically promiscuous ancestor. Linsky et al. have used a mutant hydrolase and a nonnatural substrate to trap
and crystallize a covalent intermediate common to many enzymes in the pentein superfamily. Chemical rescue experiments
either restore the original activity or trigger an alternative activity. The ability to start with a common intermediate and
then partition between two related pathways is consistent with the proposal that these enzymes may have derived from an
ancestor with a reaction intermediate capable of promiscuous partitioning.Chemistry & Biology 15, May 2008 ª2008 Elsevier Ltd All rights reserved xi
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The glycopeptide antibiotics are invaluable towards the treatment of multi-drug-resistant bacterial infections. An understand-
ing of the biosynthesis of these natural products should facilitate the bioengineering of novel glycopeptide antibiotics. Here,
Truman et al. revise the function of Cep15, a protein encoded in the gene cluster for the glycopeptide chloroeremomycin, from
a nucleotidyltransferase to a redundant minimally deactivated deacetylase. A single point mutation has been shown to reac-
tivate Cep15 into an N-acetylglucosaminyl deacetylase, its likely ancestral role. Such minimal mutagenesis to reactivate
a bacterial gene is unprecedented and indicates that other minimally mutated genes may be commonplace in bacterial sec-
ondary metabolite gene clusters.
Ribosomal Peptide Bond Synthesis through Atomic Mutagenesis
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The means by which the ribosome catalyzes peptide bond formation
has been a subject of intense discussions. By applying an ‘‘atomic
mutagenesis’’ approach to active site rRNA residues, Lang et al. re-
vealed that the ribose 20-group of A2451 must have hydrogen donor
capability. Authors propose that A2451 directly participates in an in-
tricate hydrogen bonding network, thereby positioning the P-site
tRNA substrate in its productive conformation to support amide syn-
thesis via a proton shuttle mechanism. This model appreciates the
concept of ‘‘substrate-assisted catalysis’’ and combines with it the
strict functional necessity of the ribose 20-group at A2451 to own hy-
drogen donor capacity. (Figure credits Lang et al.)
Ribosomal Peptide Bond Synthesis
through Brønsted Coefficient Analysis
PAGE 493
The ribosome has an active site comprised of RNA that catalyzes peptide bond formation. To understand how RNA promotes
this reaction requires a detailed understanding of the chemical transition state. Utilizing novel puromycin derivatives, Kingery
et al. have measured the Brønsted coefficient of the a-amino nucleophile (bnuc) for the peptidyl transferase reaction on
both 50S and 70S ribosomes. This bnuc value provides a clear and important constraint on the transition state of the ribosomal
peptidyl transferase reaction and establishes that the catalyzed and uncatalyzed reactions proceed through a different
transition state.
Neural Pathology Meets Proteasome Inhibitor
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Given the effectiveness of nerve growth factor (NGF) for treating neuronal pathologies, interest exists in developing therapeu-
tics that mimic NGF and characterizes its mechanism of action. Herein, Hines et al. show that fellutamide B, isolated from
P. fellutanum, potently induces production of NGF from cells by directly inhibiting the 20S proteasome. While the list of small
molecules shown to directly cause neurite outgrowth or differentiation of preneuronal cells is growing, fellutamide B has the
advantage of upregulating the naturally occuring neurotrophin. With the suitability of proteasome inhibitors as therapeutics
already established (e.g., for cancer), the findings suggest they also could be developed for treating neurological disorders.
Heme + Virus = Electroactive Particle in
Nanoscale
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Virus capsids are hollow particles composed of multiple copies of identical pro-
teins arranged in highly symmetric patterns. When a genetic mutation is intro-
duced into the coat protein sequence, the amino acid change is propagated
around the particle, and the position of the mutation can be selected to cause
interactions between the newly introduced residues. Prasuhn et al. describe
installation of a histidine-containing, C-terminal extension on the hepatitis B
coat protein that creates 80 sites on the particle with high local concentrations
of imidazoles, which are each shown to tightly bind iron heme molecules. In this
way, a polyvalent electroactive particle is easily assembled, laying the foundation
for further construction of nanomaterials with catalytic, electron-transfer, or light-
harvesting capabilities. (Figure adopted from Prasuhn et al.)xii Chemistry & Biology 15, May 2008 ª2008 Elsevier Ltd All rights reserved
